Cyprus tops the European Union in one of the most worrying indicators of microbial resistance, with blood infections from klebsiella resistant to strong antibiotics continuously increasing and their incidence reaching nearly six times the European average.
The new data from the European Centre for Disease Prevention and Control (ECDC), released yesterday, paint a particularly dire picture for Cyprus, at a time when antimicrobial resistance continues to spread across Europe and the targets set for 2030 are moving away rather than approaching.
Our country records an estimated incidence of 21.29 blood infections per 100,000 inhabitants for 2025 from Klebsiella pneumoniae resistant to carbapenems, compared to about 3.7 per 100,000 inhabitants in the European average.
This is the highest index among the EU countries and the European Economic Area included in this record.
Even more worrying is the index's trajectory in recent years, since, according to official ECDC data, it stood at 5.51 in 2021, had already reached 19.81 in 2024, and rose further to 21.29 in 2025.
This development gains particular significance because carbapenems are a category of powerful antibiotics used to treat serious infections. Bacterial resistance to them limits available treatment options and makes it harder to treat patients with severe infections.
Klebsiella is a bacterium that can cause serious infections, such as pneumonia, urinary tract infections, and blood infections, which in some cases progress to life-threatening sepsis.
It becomes especially dangerous when it develops resistance to carbapenems, a class of powerful antibiotics used to treat serious infections.
Its resistant strains, in fact, pose a significant challenge for hospitals, as they more frequently affect patients with compromised health and limit available therapeutic options.
Worrying picture in other bacteria as well
Klebsiella is not the only case where Cyprus records particularly high performances.
According to the latest ECDC data, the estimated incidence of blood infections from third-generation Escherichia coli resistant to cephalosporins reached 23.30 per 100,000 inhabitants in 2025, compared to 19.56 in 2024 and 9.37 in 2021.
The corresponding European rate is about 12 infections per 100,000 inhabitants.
Escherichia coli (E. coli), also known as coliformer, is a bacterium that normally exists in the intestine, but some strains can mainly cause urinary tract infections and, in more severe cases, infections of the kidneys and blood.
The course of infections from Klebsiella is also on the rise, this time resistant to third-generation cephalosporins. In Cyprus, the incidence increased from 11.46 in 2021 to 30.28 in 2025, with the European average around 9.2.
The rate of blood infections from methicillin-resistant Staphylococcus aureus (MRSA) remains particularly high. Cyprus recorded 12.07 infections per 100,000 inhabitants in 2025, compared to the European average of about 4.5.
In the case of MRSA, however, there is a decrease compared to 2024, when the Cypriot index stood at 13.63.
On the positive side
The picture is not uniformly negative. Infection rates from Acinetobacter, resistant to carbapenems, show significant improvement, with the incidence in Cyprus dropping from 29.61 per 100,000 inhabitants in 2021 to 7.57 in 2025.
Despite the decrease, this indicator remains higher than the European average.
This is a bacterium that mainly causes infections in hospitalized patients, especially in Intensive Care Units. It can cause pneumonia, wound infections, and severe blood infections.
Europe is moving away from its goals
The Cypriot data are part of a broader European picture that is causing concern among the competent public health authorities, both at the EU level and at the level of member states.
According to the ECDC, blood infections from carbapenem-resistant klebsiella increased by 72% in the European Union between 2019 and 2025, while the 2030 target foresees a 5% reduction.
Similarly, infections from third-generation E. coli resistant to cephalosporins increased by 16.4%, although the European target is to reduce them by 10%.
The picture for MRSA is better, with the incidence of blood infections having decreased by 19% since 2019. However, the ECDC warns that the increase recorded over the past two years may jeopardize the progress made.
Hospitals and hospital-acquired infections
Microbial resistance is of particular importance for hospitals, as many of the bacteria included in the new records can cause serious infections in vulnerable patients and spread within healthcare facilities.
The ECDC emphasizes the need to implement effective infection prevention and control measures, adequate staffing of relevant services, the ability to isolate patients, strengthen laboratory testing, and ensure rational use of antibiotics.
The problem of hospital-acquired infections had also been highlighted in previous European prevalence surveys, with the most recent major record being from the period 2022–2023.
Experts warn
On the occasion of the European Antibiotic Awareness Day, the ECDC warns that the spread of resistant bacteria is gradually limiting treatment options and requires coordinated action from health systems.
The European agency points out that tackling microbial resistance is not limited to reducing antibiotic consumption but requires robust surveillance systems, effective infection prevention, and timely identification of resistant microorganisms.
The seriousness of the problem of microbial resistance and its consequences for public health is emphasized by Konstantinos Tsioutis, scientific coordinator of the European Union for Disease Control and Control (EUCIC) and dean of the Medical School of the European University Cyprus.
As he pointed out, microbial resistance ranks among the ten greatest threats to public health worldwide, as more and more microorganisms stop responding to the drugs used to treat them.
He warned that without effective antimicrobial drugs, even key achievements of modern medicine, such as transplants, chemotherapy, and surgeries, risk becoming precarious.
Referring to Cyprus, he noted that the country consistently ranks among the European Union member states with the highest antibiotic consumption, the highest rates of antimicrobial resistance, and the highest frequency of hospital-acquired infections.
He expressed particular concern about the excessive use of broad-spectrum antibiotics, both in the community and in hospitals, as well as their administration in cases of viral infections, such as the common cold and flu, for which they have no effectiveness.
He also advised caution against unnecessary antibiotic administration to children, as it can disrupt their microbiome, while emphasizing that the use of antimicrobials in livestock farming and agriculture also affects the environment.
According to Mr. Tsioutis, "despite the measures being taken in Cyprus to strengthen surveillance and the operation of Antibiotic Logistics Teams and infection control teams in hospitals, addressing microbial resistance and hospital-acquired infections requires intensive, coordinated, and continuous efforts to ensure the effectiveness of antibiotics and patient safety."
